Purified transfected mouse B7-DC cell line
≥ 5.0 mg/ml
<0.1 EU/µg as determined by the LAL method
≥95% monomer by analytical SEC
>95% by SDS Page
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for this CD273 antibody clone TY25 for staining cells in flow cytometry is ≤ 0.25 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
Other Applications Reported In Literature ?
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Clone TY25 recognizes an epitope on mouse PD-L2. TY25 does not cross-react with PD-L1.
PD-L2 is expressed on macrophages and a subset of dendritic cells (DCs).
PD-L2 antibody, clone TY25, recognizes mouse programmed death ligand 2 (PDL-2), also known as B7-DC and CD273. PD-L2 is a 42 kDa type I transmembrane glycoprotein that belongs to the B7 family of the immunoglobulin (Ig) receptor superfamily. PD-L2 is an inhibitory ligand primarily expressed on antigen-presenting cells, including macrophages and a subset of dendritic cells (DCs). Its receptor, PD-1, is expressed by CD4-CD8- thymocytes as well as CD4 and CD8 T cells, monocytes, DCs, and B cells upon activation1. Binding of PD-L2 to PD-1 on CD4 and CD8 T cells inhibits T cell receptor (TCR) signaling, negatively regulating T cell proliferation, cytokine production, and cytotoxic activity2. PD-L2 is expressed on many tumor types3,4 and is associated with unfavorable prognosis in patients with solid tumors5.
PD-1, uncharacterized receptor
NCBI Gene Bank ID
References & Citations
1.) Francisco LM, et al. (2010) Immunol Rev. 236:219-242
2.) Latchman Y, et al. (2001) Nat Immunol. 2(3):261-8
3.) Ahmad SM, et al. (2018) Oncoimmunology. 7:e1390641
4.) Panjwani PK, et al. (2018) Hum Pathol. 71:91–9
5.) Yang H, et al. (2019) Front Oncol. 9:47
6.) Gubin et al. (2018) Cell. 175:1014–1030 Journal Link
Products are for research use only. Not for use in diagnostic or therapeutic procedures.